TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Pipeline Expansion and Clinical Milestones in Mid-Year Shareholder Update
Kairos Pharma (NYSE American: KAPA) provided a mid-year 2026 update highlighting plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics targeting EGFR-mutated lung cancer and other cancers. The company said CL-741 would complement its existing portfolio, which includes ENV-105, KROS-201, KROS-102 and ENV-205. Looking ahead, Kairos expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings and pursue pharmaceutical collaborations. The company also noted it has…

